By region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America accounted for the largest market share of 37.77% in 2022 owing to the presence of active industry players in the region and the availability of the products propelling the market's growth in North America. Additionally, the region’s major growth is positively influenced by increasing incidences of cardiovascular diseases (CVD), which increase the demand for cardiopulmonary exercise testing (CPET) software and CPET metabolic carts.
The CPET metabolic carts and software are utilized in CVDs in order to offer an evaluation of the respiratory, cardiovascular, and skeletal muscle systems' integrated exercise responses. According to the American Heart Association, coronary heart disease was one of the leading causes of death in the US in 2020 and account for 41.2% of deaths, followed by stroke (17.3%), other cardiovascular diseases (16.8%), high blood pressure (12.9%), heart failure (9.2%), and artery diseases (2.6%). Therefore, increasing product launch to meet the demand of physician and patients are fostering the region’s growth.
Further, the major countries studied are: The US, Canada, Brazil, Germany, France, the UK, Italy, Spain, China, India, Japan, South Korea, Australia.
FIGURE 3: CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION, 2022 & 2032 (USD BILLION)
Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review
The Europe region shows significant growth during the forecast period. This is due to the rising prevalence of chronic diseases such as cardiovascular diseases, respiratory disorders, and metabolic conditions that is driving the demand for CPET in Europe. CPET provides valuable diagnostic and prognostic information for these conditions, aiding in personalized treatment and management strategies. As per the European Survey of Cardiovascular Disease by Daiichi Sankyo Europe GmbH (Germany), there were approximately 60 million people living with CVD, and 13 million new cases were diagnosed in 2020.
Furthermore, according to MedTech Europe, adults aged 65 and older account for more than 80% of coronary artery disease (CAD) cases and more than 75% of congestive heart failure (CHF) cases in Europe. Moreover, the prevalence of CVDs in type 2 (T2) diabetes is as high as 32% in the European population. MedTech Europe reported in September 2022 that approximately 1 out of 3 people—that is, 36% of the European population—accounted for undiagnosed T2, and insulin dependency accounted for 20–30% of the diagnosed T2 population.
Furthermore, the France Cardiopulmonary Exercise Testing Market held the largest market share in 2022 and Germany Cardiopulmonary Exercise Testing Market is the fastest growing market in the Europe region.
The growth of the market in Asia-Pacific is predicted to rise rapidly due to an owing to high applications of CPET in the geriatric population as aging populations are more prone to CVDs. As per the Asia-Pacific Report on Population Ageing 2022, there were approximately 670 million people aged 60 or older in Asia-Pacific in 2022. Furthermore, the chances of having CVDs increase in diabetic patients, which increases the demand for CPET devices.
As per the Diabetes Atlas 2021, there were 90 million people diagnosed with diabetes in 2021, expected to reach 113 million by 2030 and 151 million by 2045, which is a flourishing opportunity for the Asia-Pacific market. Moreover, India Cardiopulmonary Exercise Testing Market held the largest market share in 2022 and China Cardiopulmonary Exercise Testing Market is the fastest growing market in the Asia-Pacific region.
